Talasaz AmirAli 4

4 · Guardant Health, Inc. · Filed Jul 2, 2026

AI-generated summary of this filing

Updated Jul 2, 2026

Guardant Health (GH) CEO AmirAli Receives RSU Shares; Tax Withheld

What Happened

Talasaz AmirAli, CEO of Guardant Health, had restricted stock units convert/exercise into 36,529 shares across transactions on June 30 and July 1, 2026. The company withheld 18,514 of those shares to satisfy tax withholding obligations, resulting in withholding proceeds of $214,243 (1,428 shares at $150.03) on 6/30 and $2,917,776 (17,086 shares at $170.77) on 7/01 — total withholding value $3,132,019. Net new shares retained by AmirAli after withholding: 18,015.

Key Details

Transaction dates and prices:
- 2026-06-30: 2,817 derivative shares converted (acquired); 1,428 shares withheld @ $150.03 = $214,243 (tax withholding).
- 2026-07-01: 23,997 and 9,715 derivative shares converted (acquired); 17,086 shares withheld @ $170.77 = $2,917,776 (tax withholding).
Transaction codes: M = exercise/conversion of derivative (RSU conversion), F = payment of tax liability via share withholding.
Shares owned after transaction: not specified in this filing.
Footnotes:
- F1: Company retained shares to meet the award-holder’s tax withholding obligation; retention amount not in excess of tax liability.
- F2: Some shares stem from an RSU grant on March 17, 2026 that vests in quarterly installments (Mar 31, Jun 30, Sep 30, Dec 31, 2026).
- F4/F5: Other converted RSUs relate to earlier grants (Mar 18, 2024 and Mar 12, 2025) with multi-year vesting schedules.
Filing date: 2026-07-02 (covers transactions through 6/30–7/01); no late-filing flag noted in the information provided.

Context

These transactions reflect routine RSU vesting/conversion and net-share settlement for tax purposes (company withheld shares to cover taxes). That withholding is not an open-market sale by the insider and should be viewed as a tax-related disposition rather than a discretionary sale. The material cash-equivalent value here is the ~$3.13M in tax withholding; net shares added to the CEO’s holdings from this vesting were 18,015.

Form 4

Period: 2026-06-30

DirectorCo-Chief Executive Officer

Transactions

Exercise/Conversion
Common Stock
2026-06-30+2,817→ 1,884,153 total(indirect: By Trust)
Tax Payment
Common Stock
[F1]
2026-06-30$150.03/sh−1,428$214,243→ 1,882,725 total(indirect: By Trust)
Exercise/Conversion
Common Stock
2026-07-01+23,997→ 1,906,722 total(indirect: By Trust)
Exercise/Conversion
Common Stock
2026-07-01+9,715→ 1,916,437 total(indirect: By Trust)
Tax Payment
Common Stock
[F1]
2026-07-01$170.77/sh−17,086$2,917,776→ 1,899,351 total(indirect: By Trust)
Exercise/Conversion
Restricted Stock Units
[F2][F3]
2026-06-30−2,817→ 5,634 total
Exercise: $0.00→ Common Stock (2,817 underlying)
Exercise/Conversion
Restricted Stock Units
[F4][F3]
2026-07-01−23,997→ 47,995 total
Exercise: $0.00→ Common Stock (23,997 underlying)
Exercise/Conversion
Restricted Stock Units
[F5][F3]
2026-07-01−9,715→ 58,296 total
Exercise: $0.00→ Common Stock (9,715 underlying)

Footnotes (5)

[F1]These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
[F2]This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
[F3]Not applicable for Restricted Stock Units.
[F4]This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
[F5]This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Signature

/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz|2026-07-02

1 file